EMpower Parents: Effectiveness of EMDR treatment for parental PTSD related to a child's medical condition in a randomized controlled trial

EMpower Parents:一项随机对照试验研究了EMDR疗法对因子女疾病而导致的父母创伤后应激障碍的疗效

阅读:2

Abstract

BACKGROUND: Chronic or acute medical conditions greatly impact the diagnosed child and their parents. Parents have to deal with an accumulation of stressful and potential traumatic events, which can lead to post-traumatic stress symptoms (PTSS) or post-traumatic stress disorder (PTSD). A first-choice evidence-based treatment for PTSD is Eye Movement Desensitization and Reprocessing (EMDR), usually delivered in multiple sessions over weeks or months. Currently, parents do not receive this treatment due to barriers, such as time constraints, limited focus on own wellbeing, and lack of reimbursed care at children hospitals. We will study the effect of brief EMDR treatment (offered in-person or online, compared to waitlist control) in reducing PTSD symptoms and comorbid symptoms. METHODS: In this three-armed parallel randomized controlled trial, parents start with an eligibility assessment (Tscreen), including meeting at least one of the following criteria: increased score on one symptom in each PTSD cluster, fulfillment of three of the four PTSD criteria, or total score >24 on the PCL-5. After baseline measurement (T0), eligible parents will be randomized into one of three groups: EMDR in-person (EMDRip), remote EMDR (EMDRr), or a control group (waiting list). Parents assigned to EMDRip and EMDRr will immediately start brief EMDR treatment and complete follow-up measurements at two weeks (T1ip/T1r), three months (T2ip/T2r), and six months post-treatment (T3ip/T3r). Parents in the waiting list condition complete follow-up measurements at six weeks (T1c) and 16 weeks (T2c) post baseline, assessment timepoints for the waitlist correspond to those of the intervention groups, and will be re-randomized to EMDRip or EMDRr after T2c. They will complete follow-up questionnaires at two weeks (T1.1c) and three months (T2.1c) post-treatment. Primary outcome is PTSD symptom severity. Secondary outcomes include psychological comorbidities, parenting stress, the child's posttraumatic stress, and relationship quality (parent-spouse and parent-child). Additional objectives include assessing the feasibility of EMDRip and EMDRr, as well as exploring traumatic experiences and flash forward as treatment targets. DISCUSSION: If brief EMDR treatment is found to be effective for parents of children with a chronic or acute medical condition the implementation of screening and treatment for parents should be integrated in clinical practice. TRIAL REGISTRATION: clinicaltrials.gov (NCT06776744), registered on January 14th, 2025. https://clinicaltrials.gov/study/NCT06776744.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。